<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unipolar depression in adults and initial treatment: General principles and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unipolar depression in adults and initial treatment: General principles and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unipolar depression in adults and initial treatment: General principles and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">A John Rush, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H221196"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Unipolar major depression is highly prevalent; in high-income countries, the lifetime prevalence of depression is approximately 11 percent, and in low- to middle-income countries is 15 percent [<a href="#rid1">1,2</a>]. The World Health Organization estimates that depression affects 280 million people worldwide each year [<a href="#rid1">1,3</a>].</p><p>In addition, disability caused by depression is common. Among 369 diseases and causes of injury in 204 countries and territories, unipolar depressive disorders are the 13<sup>th</sup> greatest cause of disability and mortality in the world [<a href="#rid4">4</a>]. In the United States, depression was ranked as the 2<sup>nd</sup> leading cause of years lived with disability [<a href="#rid5">5</a>]. The coronavirus 2019 (COVID-19) pandemic has increased the prevalence and in turn, the disability and mortality of unipolar major depression worldwide [<a href="#rid6">6</a>].</p><p>Major depression often follows a recurrent or chronic course. Recovery from an initial episode is followed by a recurrence within two years in more than 40 percent of patients [<a href="#rid7">7</a>]. After recovery from the first recurrence, approximately 75 percent will have a second recurrence within five years.</p><p>Nearly 70 percent of individuals with unipolar major depression receive treatment that they regard as beneficial [<a href="#rid8">8</a>]. However, some patients may need to work with 10 or more different clinicians before obtaining helpful treatment.</p><p>This topic reviews the general principles and prognosis for the initial treatment of depression. Choosing a specific therapy for the initial treatment of depression is discussed separately, as is the evidence for standard therapies that are used for initially treating depression in primary care patients and in patients with general medical illnesses. Continuation and maintenance treatment of major depression, the treatment of resistant depression, and the clinical manifestations and diagnosis of depression are also discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/90154.html" rel="external">"Unipolar depression in adult primary care patients and general medical illness: Evidence for the efficacy of initial treatments"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14674.html" rel="external">"Unipolar depression in adults: Continuation and maintenance treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/91774.html" rel="external">"Unipolar depression in adults: Clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H221202"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H221208"><span class="h2">Recognition/screening</span><span class="headingEndMark"> — </span>To screen for major depression, we typically use the self-report, two-item Patient Health Questionnaire (PHQ-2)  (<a class="graphic graphic_table graphicRef89663" href="/d/graphic/89663.html" rel="external">table 1</a>) or the self-report, nine-item PHQ-9  (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 2</a>). The PHQ-2 uses items one (feeling down, depressed, or hopeless) and two (decreased interest) from the PHQ-9. On the PHQ-2, a score of 3 or more (out of a possible score of 0 to 6) indicates a positive screen, which should be followed by a clinical interview facilitated with the full PHQ-9, to determine if the patient has major depression [<a href="#rid9">9-11</a>]. Scores ≥10 on the PHQ-9 suggest patients are likely suffering from major depression, whereas a score &lt;5 indicates euthymia. Additional information about screening for depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/83887.html" rel="external">"Screening for depression in adults"</a>.)</p><p>The PHQ-9 and other standardized instruments can also be used to measure response to therapy and guide treatment. (See <a class="local">'Optimizing treatment implementation'</a> below.)</p><p class="headingAnchor" id="H3005144214"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The evaluation of depressed patients should include a psychiatric and general medical history as well as a mental status examination. Based upon the findings, a physical examination and focused laboratory testing may be indicated to rule out general medical causes as well as medications that can cause depression. (See  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis", section on 'Assessment'</a>.)</p><p class="headingAnchor" id="H4159474522"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>We diagnose unipolar major depression according to the criteria in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)  (<a class="graphic graphic_table graphicRef89994" href="/d/graphic/89994.html" rel="external">table 3</a>) [<a href="#rid12">12</a>]. However, a reasonable alternative is to use the criteria in the World Health Organization’s International Classification of Diseases-11<sup>th</sup> Revision (ICD-11) [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis", section on 'Diagnostic criteria and classification'</a>.)</p><p class="headingAnchor" id="H853767159"><span class="h2">Comorbidity</span><span class="headingEndMark"> — </span>Major depressive episodes often co-occur with other psychiatric conditions such as generalized anxiety disorder, panic disorder, posttraumatic stress disorder, obsessive-compulsive disorder (OCD), personality disorders, and substance-related and addictive disorders [<a href="#rid14">14</a>]. Establishing the primary diagnosis when comorbid conditions are present can help focus treatment efforts. As an example, if OCD symptoms are more disabling than concomitant but less severe depressive symptoms, the initial treatment target should be OCD.</p><p>In addition, unipolar depression and general medical illnesses often co-occur. Further information about depression and comorbid psychiatric and/or general medical illnesses is discussed separately. (See  <a class="medical medical_review" href="/d/html/91774.html" rel="external">"Unipolar depression in adults: Clinical features", section on 'Comorbidity'</a>.)</p><p class="headingAnchor" id="H221214"><span class="h2">Depression subtypes</span><span class="headingEndMark"> — </span>Major depressive episodes may occur in either unipolar depressive disorders or bipolar disorders [<a href="#rid12">12</a>]. Depressed patients should be assessed for bipolar disorder because treatment of bipolar depression differs from treatment of unipolar depression. (See  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Assessment'</a> and  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p>Bipolar disorders include bipolar I disorder and bipolar II disorder [<a href="#rid12">12</a>]. Bipolar I disorder is characterized by a history of mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 4</a>), and nearly always includes episodes of hypomania (less than mania)  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 5</a>) as well as depressive episodes. Bipolar II disorder is diagnosed in patients with a history of hypomanic and depressive episodes and no history of mania.</p><p>Major depressive episodes that are part of a bipolar disorder are frequently misdiagnosed as unipolar depression. As an example, a study of 576 primary care patients with a working diagnosis of unipolar depression found that between 10 and 22 percent met criteria for bipolar disorder (depending upon how missing data were handled) [<a href="#rid15">15</a>]. Misdiagnosing bipolar major depression as unipolar depression is particularly likely in bipolar II patients, because hypomania can be difficult to distinguish from anxiety or extroverted personality traits. The differential diagnosis of bipolar disorder and unipolar depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Unipolar major depression'</a>.)</p><p>Another subtype of depression involves psychotic symptoms, which can occur during unipolar or bipolar major depressive episodes [<a href="#rid12">12</a>]. Psychotic features typically manifest with false, fixed beliefs (delusions) or less frequently, with auditory or visual hallucinations. Psychotic depression is associated with a higher risk of completed suicide and generally requires antipsychotic medications [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/14686.html" rel="external">"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment"</a>.)</p><p>Additional depression subtypes include depression with melancholic features or seasonal pattern, as well as persistent depressive disorder and minor depression. (See  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a>.)</p><p class="headingAnchor" id="H221220"><span class="h2">Suicidal ideation and behavior</span><span class="headingEndMark"> — </span>All patients with depression should be assessed for suicidal ideation and behavior. However, the ability of clinicians to identify individuals at substantial short-term risk of suicide is poor. More than half of depressed outpatients experience suicidal ideation, yet the vast majority do not act on these thoughts [<a href="#rid17">17,18</a>].</p><p>Brief self-report questionnaires such as the PHQ-9  (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 2</a>) are not sufficient to discriminate imminent risk [<a href="#rid19">19</a>], but they can identify patients who need further assessment. Clinical characteristics that may help identify patients at increased risk for suicidal behavior include [<a href="#rid19">19-24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Suicidal ideation, plan, and intent</p><p class="bulletIndent1"><span class="glyph">●</span>Greater intensity of suicidal thinking (eg, multiple times per day for longer durations)</p><p class="bulletIndent1"><span class="glyph">●</span>Access to means for suicide (eg, firearms), and the lethality of those means</p><p class="bulletIndent1"><span class="glyph">●</span>Psychotic symptoms (eg, delusions or command auditory hallucinations)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe anxiety</p><p class="bulletIndent1"><span class="glyph">●</span>Substance-related and addictive disorders</p><p class="bulletIndent1"><span class="glyph">●</span>History and seriousness of previous suicide attempts</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of or recent exposure to suicide</p><p></p><p>Patients at immediate risk of suicide should be evaluated in an emergency department and/or hospitalized until the patient’s safety is stabilized. Additional information about suicidal ideation and behavior, including evaluation and management, is discussed separately. (See  <a class="medical medical_review" href="/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults"</a>.)</p><p class="headingAnchor" id="H84009457"><span class="h2">Patient engagement and retention in treatment</span><span class="headingEndMark"> — </span>Patients with unipolar depression are often reluctant to engage in treatment. In a prospective study of patients who presented for initial treatment of depression (n &gt;4000), more than 10 percent did not return for treatment after the initial evaluation [<a href="#rid25">25,26</a>]. Another 30 percent did not complete the first eight weeks of treatment, indicating a failure to retain patients who were initially engaged.</p><p>If it is feasible, one technique that we use to enhance engagement is to schedule the initial visit face-to-face, rather than doing so digitally. Subsequent in-person visits may also help.</p><p>It may also help to ask about fears or misconceptions that interfere with engagement in treatment; as an example, patients often equate depression as a character defect or a sign of personal weakness. Engagement can thus be enhanced if patients understand and accept the diagnosis, by emphasizing that depression is [<a href="#rid22">22,23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Common</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Associated with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Emotional symptoms, such as anger, anxiety, and sadness</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical symptoms (eg, fatigue, headache, abdominal pain, and muscle tension), as well as increased perception and impact of physical symptoms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A potentially serious brain disease that affects the chemistry and functioning of the brain</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Analogous to other diseases such as asthma that affects the lungs, or diabetes that affects the pancreas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Often time limited</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Usually treatable with a variety of medications and/or psychotherapies</p><p></p><p>The clinical features and diagnosis of depression are discussed separately. (See  <a class="medical medical_review" href="/d/html/91774.html" rel="external">"Unipolar depression in adults: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a>.)</p><p>Another means of facilitating engagement and retention in treatment is to initially manage the depressive syndrome solely with active surveillance (watchful waiting); this is a reasonable choice for patients with mild or moderate unipolar depression (eg, PHQ-9 score 5 to 14  (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 2</a>) without suicidal plans or behavior). Active surveillance includes regular, brief follow-up visits (eg, every two to three weeks), during which clinicians assess symptoms and provide support. The goal is to help patients recognize problems with mood, sleep, appetite, energy, and cognition, as well as impaired social and occupational functioning, which may help them accept treatment. Framing medication or psychotherapy as a trial (rather than a long-term commitment) may also be useful.</p><p>Active surveillance is not appropriate for depressed patients who are severely symptomatic (eg, PHQ-9 score ≥15), chronically depressed (eg, ≥2 years), or substantially impaired (eg, unemployed). Clinicians should inform severely ill patients that delaying treatment may delay recovery [<a href="#rid27">27</a>]. As an example, a meta-analysis of three studies (two observational studies and one randomized trial, total n = 486 patients with unipolar depression) found that remission was more likely in patients with a shorter duration of untreated illness, compared to patients with a longer duration (relative risk 1.7, 95% CI 1.3-2.1) [<a href="#rid28">28</a>]. Additional information about the clinical features that distinguish severe from mild to moderate depression are discussed separately. (See  <a class="medical medical_review" href="/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment", section on 'Severe major depression'</a>.)</p><p class="headingAnchor" id="H3186924022"><span class="h2">Optimizing treatment implementation</span><span class="headingEndMark"> — </span>Depressed outpatients who start a new antidepressant should generally be seen relatively soon (eg, one to two weeks) afterwards and subsequently monitored (by phone, video, or in-person visit) at least every two to four weeks for six to eight weeks, depending upon the clinical urgency [<a href="#rid29">29,30</a>]. Clinicians should assess therapeutic response, adverse effects, and adherence, with particular attention given to suicidal ideation and behavior, psychosis, agitation, and anxiety [<a href="#rid31">31</a>]. Following remission, the frequency of assessments can be tapered. (See  <a class="medical medical_review" href="/d/html/14674.html" rel="external">"Unipolar depression in adults: Continuation and maintenance treatment", section on 'Monitoring patients'</a>.)</p><p>At each visit, we suggest that clinicians provide measurement based care, which is the systematic, quantitative assessment of symptoms and side effects [<a href="#rid32">32,33</a>]. Tolerability of treatment, adherence, psychosocial functioning, and quality of life can also be measured. Among the standardized instruments that are available to ascertain response to pharmacotherapy or psychotherapy, the PHQ-9  (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 2</a>) is the most widely used and studied. A decrease ≥50 percent during treatment is typically regarded as a meaningful response to treatment, and a score &lt;5 indicates euthymia or remission. Measurement based care is consistent with multiple practice guidelines [<a href="#rid22">22,23,31,34-36</a>].</p><p>The PHQ-9 and additional information about measurement based care are discussed separately. (See  <a class="medical medical_review" href="/d/html/14860.html" rel="external">"Using scales to monitor symptoms and treat depression (measurement based care)"</a>.)</p><p class="headingAnchor" id="H221226"><span class="h2">Adherence to treatment</span></p><p class="headingAnchor" id="H386843361"><span class="h3">Overview</span><span class="headingEndMark"> — </span>Optimal outcomes in the medication management of depressed patients require adherence to prescribed treatments [<a href="#rid25">25</a>]. However, nonadherence to medications is common. A nationally representative survey of depressed patients in the United States who initiated antidepressants (n = 829) found that the medications were discontinued within one month by 42 percent of patients, and within three months by 72 percent [<a href="#rid37">37</a>]. Clinical risk factors that are associated with poor adherence to antidepressants include concerns over side effects; comorbid substance abuse and personality disorders; various fears, misconceptions, and misguided beliefs about treatment; and a poor therapeutic alliance [<a href="#rid25">25,38,39</a>]. Sociodemographic risk factors include younger age (eg, less than 30 or 40 years) [<a href="#rid38">38,40</a>], fewer years of education [<a href="#rid26">26,37,38</a>], and race/ethnicity other than non-Hispanic White [<a href="#rid38">38,40</a>].</p><p>Poor adherence to antidepressants is associated with greater mortality. As an example, a four year study of an administrative claims database identified patients who were prescribed antidepressants and were either nonadherent (n &gt;80,000) or demonstrated good adherence (n &gt;80,000) [<a href="#rid41">41</a>]. After adjusting for potential confounding factors (eg, age, smoking status, and general medical comorbidities), the analyses showed that all-cause mortality was modestly greater in patients with poorer adherence (hazard ratio 1.14, 95% CI 1.10-1.18).</p><p class="headingAnchor" id="H3711816710"><span class="h3">Enhancing adherence</span><span class="headingEndMark"> — </span>The cornerstone of optimizing adherence is patient education about depression, and the purpose and administration of pharmacotherapy, including how to take medications and the necessity of dose adjustments based upon efficacy and adverse effects. Helping patients understand and recognize the symptoms, clinical course, treatment options, and the timing of and likelihood of various treatment outcomes serves to establish rapport and reduce ambiguity and ambivalence. Thus, if therapeutic effects are not achieved or adverse effects occur, the patient understands that there are many treatment options and that more than one treatment trial is often needed to resolve the problem. These management principles are consistent with multiple practice guidelines and reviews. [<a href="#rid22">22,23,34,35,42-45</a>].</p><p>Patients starting pharmacotherapy should be told the following [<a href="#rid33">33,46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Take the medication as prescribed rather than on an as-needed basis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There may be a lag of several weeks (eg, three weeks) before a discernible response is apparent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Side effects (eg, anxiety or agitation, headache, and stomach upset)  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 6</a>) frequently occur during the first few days, but typically resolve within a week of starting the medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a dose is missed, the next scheduled dose should not be doubled.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If medication is acutely effective, it is important to continue treatment for several (eg, six) months to prevent relapse. (See  <a class="medical medical_review" href="/d/html/14674.html" rel="external">"Unipolar depression in adults: Continuation and maintenance treatment", section on 'Continuation treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Call to discuss distressing side effects or other concerns or questions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Talk with the prescribing clinician before stopping medications.</p><p></p><p>In addition, the following techniques can enhance medication adherence [<a href="#rid22">22,23,39,45,47,48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Help patients accept the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ask about prior use of pharmacotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Take a flexible approach to customize pharmacotherapy and accommodate patient preferences when feasible. As an example, ask patients to choose from several medications with different in side effects. This shared decision-making increases patients’ willingness to take the chosen medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Simplify dosing regimens. Multiple reviews of different illnesses indicate that adherence is superior with medications administered once per day compared with more frequent doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Help patients set realistic expectations of benefits and adverse effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discuss plans for dose titrations and how the clinician will monitor the use and benefit of medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provide simple and clear written instructions for taking prescribed medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If patients are taking the antidepressant multiple times per day, or multiple medications each day, suggest pill boxes to organize daily doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suggest the use of cues (eg, smart phone alarms, a written record, or pairing pill taking with another regular activity such as eating breakfast) as reminders to take medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Explicitly discuss barriers to adherence and plans to overcome them. As an example, employ a pill box when traveling to avoid leaving pills at home.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Praise desirable behavior and results.</p><p></p><p>Motivational interviewing is used to enhance adherence in many illnesses [<a href="#rid39">39,49</a>]. The basic aim of motivational interviewing is to help patients acknowledge that adherence with pharmacotherapy is problematic, make a commitment to change their behavior, and take action to change. The general approach is to initially ask questions and to give advice later. Other elements include expressing empathy (eg, “I know this is hard”), focusing upon collaboration (Let’s work together on this”), and avoiding arguments.</p><p>Other means to enhance adherence include focusing upon the therapeutic alliance (relationship) with patients and encouraging them to actively participate in treatment as partners [<a href="#rid22">22,23,34,38,39,45</a>].</p><p>Adherence can also be improved with the use of allied health professionals to proactively monitor patients, and to schedule return visits for patients with persistent symptoms [<a href="#rid50">50</a>]. Adherence may be further enhanced by facilitating telephone access or secure messaging to the clinician for patient questions about side effects.</p><p class="headingAnchor" id="H2921740527"><span class="h3">Monitoring adherence</span><span class="headingEndMark"> — </span>Regularly scheduled follow-up contacts, especially following onset of pharmacotherapy, may improve medication adherence and allows clinicians to monitor patients and adjust doses for efficacy and side effects [<a href="#rid22">22,23,45</a>].</p><p>Asking patients about adherence in a nonjudgmental manner at each follow-up visit highlights its importance and provides an opportunity to trouble shoot adherence obstacles. Patients may be more likely to discuss concerns or problems with the medication if clinicians initially ask open-ended questions (eg, “How are you taking your medications?”), normalize poor adherence (eg, “Nearly everybody has trouble taking their medications”), and explain that information about adherence is important in treatment decisions (eg, determining the right dose or changing treatment) [<a href="#rid51">51</a>]. The last step is to explicitly ask about missed doses. For patients who acknowledge poor adherence, follow-up questions should explore the reasons (eg, “What gets in the way of taking your medications?” or “Did you feel better when you stopped the medicines?”). Clinicians may ascribe noncompliance to incorrect reasons.</p><p>The frequency of monitoring adherence depends upon the patient’s clinical status and presumed level of adherence. Noticeable worsening in symptoms or missed appointments should prompt an assessment. Patients whose adherence is problematic or who are not responding to treatment are monitored weekly. Relatively new patients who regularly adhere to treatment are monitored monthly. Well-known patients who are thought to be fully compliant are generally assessed every two to three months.</p><p class="headingAnchor" id="H497077641"><span class="h2">Referral to specialty care</span><span class="headingEndMark"> — </span>Most patients with unipolar depression can be successfully treated in primary care settings. A prospective observational study of depressed patients administered full doses of <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> for up to 14 weeks in primary care settings (n = 1091 patients) or psychiatric clinics (n = 1785 patients); both settings implemented measurement based care and scheduled medication visits every two to three weeks [<a href="#rid52">52</a>]. Remission in the two groups were nearly identical (approximately 27 percent).</p><p>Nevertheless, some patients presenting to primary care clinicians for initial treatment of major depression are typically referred to a psychiatrist or other mental health clinician. Indications for referral include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Suspicion of bipolar disorder (eg, history of mania or hypomania). (See  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Assessment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe depression (eg, PHQ score ≥20  (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment", section on 'Severe major depression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Depression with complicating features that require more frequent and longer visits, such as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suicidal thoughts and behavior. (See  <a class="medical medical_review" href="/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Psychotic depression, which can include delusions or hallucinations. (See  <a class="medical medical_review" href="/d/html/14686.html" rel="external">"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unipolar major depression with mixed features (ie, depression accompanied by subthreshold [not meeting full criteria] symptoms of hypomania/mania). (See  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis", section on 'Depressive episode subtypes (specifiers)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comorbid psychiatric disorders, such as anxiety, personality, and/or substance use disorders (comorbidities in depressed patients who are treated with antidepressants are associated with poorer outcomes [<a href="#rid53">53</a>]). (See  <a class="medical medical_review" href="/d/html/91774.html" rel="external">"Unipolar depression in adults: Clinical features", section on 'Comorbidity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient preference for psychotherapy, either as the primary treatment or in combination with antidepressant medication. (See  <a class="medical medical_review" href="/d/html/14612.html" rel="external">"Overview of psychotherapies"</a> and  <a class="medical medical_review" href="/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment", section on 'Psychotherapy'</a>.)</p><p></p><p>Collaboration between primary care and mental health clinicians is critical in facilitating a successful referral and subsequently, returning the patient to primary care when appropriate.</p><p class="headingAnchor" id="H221262"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>In patients with mild to moderate unipolar major depression (eg, Patient Health Questionnaire [PHQ] score 5 to 14  (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 2</a>), and no psychotic features or suicidal behavior), initial treatment with antidepressants leads to response or remission in approximately 50 to 60 percent:</p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of 182 randomized trials (n &gt;23,000 patients treated with antidepressants for an average of seven weeks) found that response (reduction of baseline symptoms ≥50 percent) occurred in 54 percent of patients [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a pooled analysis of 93 randomized trials that included more than 20,000 patients who were treated with second-generation antidepressants (<a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="8944" href="/d/drug information/8944.html" rel="external">desvenlafaxine</a>, <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="9684" href="/d/drug information/9684.html" rel="external">nefazodone</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="10013" href="/d/drug information/10013.html" rel="external">trazodone</a>, or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>) for 6 to 12 weeks [<a href="#rid55">55</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Remission in 47 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Response (including those who remitted) occurred in 63 percent of patients</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the prospective, observational Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 2876 outpatients (nearly 80 percent had chronic or recurrent unipolar major depression) were initially treated with full doses of <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> for up to 14 weeks [<a href="#rid56">56</a>]. Response or remission occurred in 48 percent, with a mean time to remission of seven weeks [<a href="#rid57">57</a>].</p><p></p><p>Based upon a pooled analysis of 15 randomized trials (n &gt;5600 patients treated with antidepressants or placebo), the number of prior major depressive episodes is not related to outcome of antidepressant treatment for an acute episode [<a href="#rid58">58</a>]. However, remission of a depressive episode may be more likely if treatment commences soon after onset of symptoms [<a href="#rid28">28</a>]. (See <a class="local">'Patient engagement and retention in treatment'</a> above.)</p><p class="headingAnchor" id="H750090959"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H229421"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15342.html" rel="external">"Patient education: Depression in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/83813.html" rel="external">"Patient education: When you have depression and another health problem (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4868.html" rel="external">"Patient education: Depression in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4866.html" rel="external">"Patient education: Depression treatment options for adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4872.html" rel="external">"Patient education: Electroconvulsive therapy (ECT) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H221920"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse consequences of depression</strong> – Unipolar depression is highly prevalent, disabling, and recurrent or chronic. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General treatment principles</strong> – The general principles and issues involved in treating unipolar major depression include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recognition/screening</strong> – We typically use the two- or nine-item, self-report Patient Health Questionnaire (PHQ)  (<a class="graphic graphic_table graphicRef89663" href="/d/graphic/89663.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 2</a>) to screen for major depression. (See <a class="local">'Recognition/screening'</a> above and  <a class="medical medical_review" href="/d/html/83887.html" rel="external">"Screening for depression in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation</strong> – The evaluation of depressed patients should include a psychiatric and general medical history as well as a mental status examination. Based upon the findings, a physical examination and focused laboratory testing may be indicated to rule out general medical causes as well as medications that can cause depression. (See  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis", section on 'Assessment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – To diagnose unipolar major depression, we typically use the criteria from the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)  (<a class="graphic graphic_table graphicRef89994" href="/d/graphic/89994.html" rel="external">table 3</a>). (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis", section on 'Diagnostic criteria and classification'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Comorbidity</strong> – Major depressive episodes often co-occur with other psychiatric conditions such as generalized anxiety disorder, panic disorder, and/or personality disorders, as well as general medical illnesses. (See <a class="local">'Comorbidity'</a> above and  <a class="medical medical_review" href="/d/html/91774.html" rel="external">"Unipolar depression in adults: Clinical features", section on 'Comorbidity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Depression subtypes</strong> – Depression can occur in patients with bipolar disorder as well as those with unipolar depression. Rule out bipolar disorder by ruling out a history of mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 4</a>) and hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 5</a>). (See <a class="local">'Depression subtypes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suicidality</strong> – Assess all depressed patients for suicidal ideation and behavior. (See <a class="local">'Suicidal ideation and behavior'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Engagement and retention in treatment</strong> – Engage and retain patients in treatment by educating them about the diagnosis of and treatment options for depression. (See <a class="local">'Patient engagement and retention in treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring</strong> – Monitor patient outcomes during treatment with a standardized instrument such as the PHQ-9  (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 2</a>). (See <a class="local">'Optimizing treatment implementation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adherence to treatment</strong> – At the onset of therapy, encourage adherence to treatment by educating patients and setting realistic expectations about the potential benefits and adverse effects.</p><p></p><p class="bulletIndent2">Patients starting pharmacotherapy should be told the following: take the medication as prescribed; there may be a lag of several weeks before a discernible response is apparent; side effects  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 6</a>) frequently occur during the first few days, but typically resolve within a week of starting the medication; continue treatment despite feeling better; and call to discuss side effects, other concerns, or questions.</p><p></p><p class="bulletIndent2">Other techniques for promoting adherence include taking a flexible approach and customizing pharmacotherapy to accommodate patient preferences to the extent that they are feasible, providing simple and clear written instructions for taking prescribed medications, and motivational interviewing.</p><p></p><p>(See <a class="local">'Adherence to treatment'</a> above.)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Making referrals</strong> – Refer patients who need specialty care, including those with suicidal behavior or psychotic features. (See <a class="local">'Referral to specialty care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Initial treatment of mild to moderate unipolar major depression with antidepressants leads to response or remission in approximately 50 to 60 percent of patients. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H628208513"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Wayne Katon, MD, now deceased, who contributed to an earlier version of this topic review. The UpToDate editorial staff also acknowledges Gregory Simon, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013; 34:119.</a></li><li><a class="nounderline abstract_t">Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011; 9:90.</a></li><li class="breakAll">World Health Organization. Depression. September 13, 2021. https://www.who.int/news-room/fact-sheets/detail/depression (Accessed on February 24, 2023).</li><li><a class="nounderline abstract_t">GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396:1204.</a></li><li><a class="nounderline abstract_t">GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390:1211.</a></li><li><a class="nounderline abstract_t">COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021; 398:1700.</a></li><li><a class="nounderline abstract_t">Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157:229.</a></li><li><a class="nounderline abstract_t">Harris MG, Kazdin AE, Chiu WT, et al. Findings From World Mental Health Surveys of the Perceived Helpfulness of Treatment for Patients With Major Depressive Disorder. JAMA Psychiatry 2020; 77:830.</a></li><li><a class="nounderline abstract_t">Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282:1737.</a></li><li><a class="nounderline abstract_t">Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.</a></li><li><a class="nounderline abstract_t">Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003; 41:1284.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li class="breakAll">World Health Organization. International Classification of Diseases 11th Revision. Mental, behavioral or neurodevelopmental disorders. https://icd.who.int/browse11/l-m/en (Accessed on February 21, 2023).</li><li><a class="nounderline abstract_t">Rush AJ, Zimmerman M, Wisniewski SR, et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord 2005; 87:43.</a></li><li><a class="nounderline abstract_t">Smith DJ, Griffiths E, Kelly M, et al. Unrecognised bipolar disorder in primary care patients with depression. Br J Psychiatry 2011; 199:49.</a></li><li><a class="nounderline abstract_t">Gournellis R, Tournikioti K, Touloumi G, et al. Psychotic (delusional) depression and completed suicide: a systematic review and meta-analysis. Ann Gen Psychiatry 2018; 17:39.</a></li><li><a class="nounderline abstract_t">Zisook S, Trivedi MH, Warden D, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord 2009; 117:63.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/ (Accessed on April 10, 2023).</li><li><a class="nounderline abstract_t">Simon GE, Coleman KJ, Rossom RC, et al. Risk of suicide attempt and suicide death following completion of the Patient Health Questionnaire depression module in community practice. J Clin Psychiatry 2016; 77:221.</a></li><li><a class="nounderline abstract_t">Kessler RC, Stein MB, Petukhova MV, et al. Predicting suicides after outpatient mental health visits in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). Mol Psychiatry 2017; 22:544.</a></li><li><a class="nounderline abstract_t">Simon GE, Johnson E, Lawrence JM, et al. Predicting Suicide Attempts and Suicide Deaths Following Outpatient Visits Using Electronic Health Records. Am J Psychiatry 2018; 175:951.</a></li><li class="breakAll">American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. http://psychiatryonline.org/guidelines.aspx (Accessed on April 17, 2012).</li><li><a class="nounderline abstract_t">American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition. Am J Psychiatry 2010; 167 (supplement):1.</a></li><li><a class="nounderline abstract_t">Conway PM, Erlangsen A, Teasdale TW, et al. Predictive Validity of the Columbia-Suicide Severity Rating Scale for Short-Term Suicidal Behavior: A Danish Study of Adolescents at a High Risk of Suicide. Arch Suicide Res 2017; 21:455.</a></li><li><a class="nounderline abstract_t">Rush AJ, Thase ME. Improving Depression Outcome by Patient-Centered Medical Management. Am J Psychiatry 2018; 175:1187.</a></li><li><a class="nounderline abstract_t">Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry 2007; 164:1189.</a></li><li><a class="nounderline abstract_t">Ghio L, Gotelli S, Cervetti A, et al. Duration of untreated depression influences clinical outcomes and disability. J Affect Disord 2015; 175:224.</a></li><li><a class="nounderline abstract_t">Ghio L, Gotelli S, Marcenaro M, et al. Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. J Affect Disord 2014; 152-154:45.</a></li><li><a class="nounderline abstract_t">Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 149:725.</a></li><li><a class="nounderline abstract_t">Thase ME. The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists? Curr Psychiatry Rep 2011; 13:476.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline [NG222] Published: June 29, 2022. https://www.nice.org.uk/guidance/ng222 (Accessed on March 25, 2023).</li><li><a class="nounderline abstract_t">McIntyre RS. When should you move beyond first-line therapy for depression? J Clin Psychiatry 2010; 71 Suppl 1:16.</a></li><li><a class="nounderline abstract_t">Malhi GS, Hitching R, Berk M, et al. Pharmacological management of unipolar depression. Acta Psychiatr Scand Suppl 2013; :6.</a></li><li><a class="nounderline abstract_t">Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. Can J Psychiatry 2016; 61:510.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021; 55:7.</a></li><li class="breakAll">Department of Veterans Affairs. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. U.S. Government Printing Office; Department of Defense, Washington, DC, 2022.</li><li><a class="nounderline abstract_t">Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006; 163:101.</a></li><li><a class="nounderline abstract_t">Pompili M, Venturini P, Palermo M, et al. Mood disorders medications: predictors of nonadherence - review of the current literature. Expert Rev Neurother 2013; 13:809.</a></li><li class="breakAll">Velligan DI, Riolo SA, Weston CG. Adherence to medication in psychiatric disorders. In: Psychiatry, Fourth Edition, Tasman A, Kay J, Lieberman JA, et al (Eds), John Wiley &amp; Sons, West Sussex 2015. Vol 2, p.2382.</li><li><a class="nounderline abstract_t">Rossom RC, Shortreed S, Coleman KJ, et al. ANTIDEPRESSANT ADHERENCE ACROSS DIVERSE POPULATIONS AND HEALTHCARE SETTINGS. Depress Anxiety 2016; 33:765.</a></li><li><a class="nounderline abstract_t">Krivoy A, Balicer RD, Feldman B, et al. Adherence to antidepressants is associated with lower mortality: a 4-year population-based cohort study. J Clin Psychiatry 2016; 77:e566.</a></li><li><a class="nounderline abstract_t">Tursi MF, Baes Cv, Camacho FR, et al. Effectiveness of psychoeducation for depression: a systematic review. Aust N Z J Psychiatry 2013; 47:1019.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline [NG222]. June 29, 2022. https://www.nice.org.uk/guidance/ng222 (Accessed on March 06, 2023).</li><li><a class="nounderline abstract_t">Qaseem A, Owens DK, Etxeandia-Ikobaltzeta I, et al. Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med 2023; 176:239.</a></li><li class="breakAll">Levenson JL, Crouse EL, Bozymski KM. Psychopharmacolgy. In: The American Psychiatric Association Publishing Textbook of Psychiatry, Seventh Edition, Roberts LW (Ed), American Psychiatric Association Publishing, Washington, DC 2019. p.791.</li><li><a class="nounderline abstract_t">Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995; 33:67.</a></li><li><a class="nounderline abstract_t">Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.</a></li><li><a class="nounderline abstract_t">Medic G, Higashi K, Littlewood KJ, et al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat 2013; 9:119.</a></li><li class="breakAll">Pilkey D, Pearson CW, Martino S. Motivational interviewing. In: Psychiatry, Fourth Edition, Tasman A, Kay J, Lieberman JA, et al (Eds), John Wiley &amp; Sons, West Sussex 2015. Vol 2, p.1882.</li><li><a class="nounderline abstract_t">Dietrich AJ, Oxman TE, Williams JW Jr, et al. Re-engineering systems for the treatment of depression in primary care: cluster randomised controlled trial. BMJ 2004; 329:602.</a></li><li><a class="nounderline abstract_t">Hahn SR. Adherence to antidepressant medication: patient-centered shared decision making communication to improve adherence. CNS Spectr 2009; 14:6.</a></li><li><a class="nounderline abstract_t">Gaynes BN, Rush AJ, Trivedi MH, et al. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med 2008; 23:551.</a></li><li><a class="nounderline abstract_t">Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165:342.</a></li><li><a class="nounderline abstract_t">Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19:34.</a></li><li><a class="nounderline abstract_t">Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 2011; 155:772.</a></li><li><a class="nounderline abstract_t">Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.</a></li><li><a class="nounderline abstract_t">McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 2011; 31:180.</a></li><li><a class="nounderline abstract_t">Dodd S, Berk M, Kelin K, et al. Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder. J Affect Disord 2013; 150:344.</a></li></ol></div><div id="topicVersionRevision">Topic 90153 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23514317" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The epidemiology of depression across cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791035" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cross-national epidemiology of DSM-IV major depressive episode.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791035" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cross-national epidemiology of DSM-IV major depressive episode.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33069326" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28919117" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34634250" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10671391" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Multiple recurrences of major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32432716" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Findings From World Mental Health Surveys of the Perceived Helpfulness of Treatment for Patients With Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10568646" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556941" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The PHQ-9: validity of a brief depression severity measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583691" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The Patient Health Questionnaire-2: validity of a two-item depression screener.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583691" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Patient Health Questionnaire-2: validity of a two-item depression screener.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583691" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Patient Health Questionnaire-2: validity of a two-item depression screener.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894381" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292927" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Unrecognised bipolar disorder in primary care patients with depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30258483" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Psychotic (delusional) depression and completed suicide: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217668" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217668" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26930521" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk of suicide attempt and suicide death following completion of the Patient Health Questionnaire depression module in community practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27431294" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Predicting suicides after outpatient mental health visits in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29792051" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Predicting Suicide Attempts and Suicide Deaths Following Outpatient Visits Using Electronic Health Records.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29792051" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Predicting Suicide Attempts and Suicide Deaths Following Outpatient Visits Using Electronic Health Records.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27602917" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Predictive Validity of the Columbia-Suicide Severity Rating Scale for Short-Term Suicidal Behavior: A Danish Study of Adolescents at a High Risk of Suicide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30220219" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Improving Depression Outcome by Patient-Centered Medical Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671281" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25658495" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Duration of untreated depression influences clinical outcomes and disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183486" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017591" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21964929" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21964929" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20977871" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : When should you move beyond first-line therapy for depression?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23586873" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pharmacological management of unipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486151" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390896" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Continuity of antidepressant treatment for adults with depression in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23898852" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mood disorders medications: predictors of nonadherence - review of the current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23898852" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mood disorders medications: predictors of nonadherence - review of the current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27320786" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : ANTIDEPRESSANT ADHERENCE ACROSS DIVERSE POPULATIONS AND HEALTHCARE SETTINGS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27136668" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adherence to antidepressants is associated with lower mortality: a 4-year population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23739312" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effectiveness of psychoeducation for depression: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23739312" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effectiveness of psychoeducation for depression: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36689752" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36689752" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7823648" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The role of the primary care physician in patients' adherence to antidepressant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16079372" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Adherence to medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23355782" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23355782" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15345600" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Re-engineering systems for the treatment of depression in primary care: cluster randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20448515" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adherence to antidepressant medication: patient-centered shared decision making communication to improve adherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18247097" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172020" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823760" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147715" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390886" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346613" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23683993" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
